$SGMO
Sangamo Therapeutics Inc Stock $sgmo

$sgmo Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000162828021008878 Filed on May 04, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$26.28M	$13.08M
YoY Change	100.98%	62.01%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$16.15M	$16.12M
YoY Change	0.19%	-5.84%
% of Gross Profit
Research & Development	$56.43M	$41.48M
YoY Change	36.05%	19.02%
% of Gross Profit
Depreciation & Amortization	$1.875M	$1.311M
YoY Change	43.02%	83.36%
% of Gross Profit
Operating Expenses	$72.58M	$57.60M
YoY Change	26.01%	10.83%
Operating Profit	-$46.30M	-$44.52M
YoY Change	4.0%	1.42%
Interest Expense	$630.0K	$1.550M
YoY Change	-59.35%	-8.28%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$45.68M	-$42.97M
YoY Change	6.31%	1.82%
Income Tax	$262.0K	$0.00
% Of Pretax Income
Net Earnings	-$45.93M	-$42.91M
YoY Change	7.04%	1.81%
Net Earnings / Revenue	-174.78%	-328.18%
Basic Earnings Per Share	-$0.32
Diluted Earnings Per Share	-$0.32	-$369.7K
COMMON SHARES
Basic Shares Outstanding	143.1M shares	116.0M shares
Diluted Shares Outstanding	143.1M shares

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$587.1M	$358.1M
YoY Change	63.93%	2.03%
Cash & Equivalents	$123.0M	$85.75M
Short-Term Investments	$464.1M	$272.4M
Other Short-Term Assets	$12.10M	$4.900M
YoY Change	146.94%	32.43%
Inventory
Prepaid Expenses
Receivables	$6.746M	$6.970M
Other Receivables	$1.000M	$900.0K
Total Short-Term Assets	$606.9M	$370.9M
YoY Change	63.62%	2.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$45.22M	$31.29M
YoY Change	44.51%	-32.7%
Goodwill	$40.99M	$38.55M
YoY Change	6.34%
Intangibles	$55.58M	$52.14M
YoY Change	6.61%	-1.94%
Long-Term Investments	$42.40M	$5.000M
YoY Change	748.0%
Other Assets	$14.10M	$9.470M
YoY Change	48.86%	-77.01%
Total Long-Term Assets	$270.2M	$213.3M
YoY Change	26.64%	18.45%
TOTAL ASSETS
Total Short-Term Assets	$606.9M	$370.9M
Total Long-Term Assets	$270.2M	$213.3M
Total Assets	$877.1M	$584.3M
YoY Change	50.12%	7.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.64M	$13.60M
YoY Change	-14.43%	-54.82%
Accrued Expenses	$13.76M	$11.90M
YoY Change	15.63%	91.94%
Deferred Revenue	$94.36M	$36.55M
YoY Change	158.18%	-33.33%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$132.8M	$62.07M
YoY Change	114.03%	-31.87%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$7.228M	$5.880M
YoY Change	22.93%	207.69%
Total Long-Term Liabilities	$7.228M	$5.880M
YoY Change	22.93%	207.69%
TOTAL LIABILITIES
Total Short-Term Liabilities	$132.8M	$62.07M
Total Long-Term Liabilities	$7.228M	$5.880M
Total Liabilities	$407.7M	$189.9M
YoY Change	114.72%	-11.36%
SHAREHOLDERS EQUITY
Retained Earnings	-$823.9M	-$699.9M
YoY Change	17.72%
Common Stock	$1.294B	$1.098B
YoY Change	17.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$470.4M	$394.3M
YoY Change
Total Liabilities & Shareholders Equity	$877.1M	$584.3M
YoY Change	50.12%	7.66%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$45.93M	-$42.91M
YoY Change	7.04%	1.81%
Depreciation, Depletion And Amortization	$1.875M	$1.311M
YoY Change	43.02%	83.36%
Cash From Operating Activities	-$68.55M	-$18.89M
YoY Change	262.89%	-58.13%
INVESTING ACTIVITIES
Capital Expenditures	$7.950M	$3.775M
YoY Change	110.6%	-36.84%
Acquisitions
YoY Change
Other Investing Activities	$53.20M	$27.50M
YoY Change	93.45%	-412.5%
Cash From Investing Activities	$45.29M	$23.72M
YoY Change	90.93%	-260.28%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$15.65M	$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$15.24M	$409.0K
YoY Change	3624.94%	89.35%
NET CHANGE
Cash From Operating Activities	-$68.55M	-$18.89M
Cash From Investing Activities	$45.29M	$23.72M
Cash From Financing Activities	$15.24M	$409.0K
Net Change In Cash	-$8.354M	$5.321M
YoY Change	-257.0%	-108.95%
FREE CASH FLOW
Cash From Operating Activities	-$68.55M	-$18.89M
Capital Expenditures	$7.950M	$3.775M
Free Cash Flow	-$76.50M	-$22.67M
YoY Change	237.52%	-55.64%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001001233
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	000-30171
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	SANGAMO THERAPEUTICS, INC.
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	68-0359556
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	7000 Marina Blvd.
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Brisbane
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94005
CY2021Q1	dei	City Area Code CityAreaCode	510
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	970-6000
CY2021Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2021Q1	dei	Trading Symbol TradingSymbol	SGMO
CY2021Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	143881477	shares
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	122975000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	131329000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	464109000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	510094000	USD
CY2021Q1	us-gaap	Interest Receivable Current InterestReceivableCurrent	974000	USD
CY2020Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	1035000	USD
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6746000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5224000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	70324000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	71045000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12140000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11986000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	606944000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	659668000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	42431000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	50530000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	45222000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	41324000	USD
CY2021Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	55583000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	58128000	USD
CY2021Q1	us-gaap	Goodwill Goodwill	40994000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	42798000	USD
CY2021Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1500000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	14097000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13557000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1500000	USD
CY2021Q1	us-gaap	Assets Assets	877095000	USD
CY2020Q4	us-gaap	Assets Assets	938550000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	11638000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12553000	USD
CY2021Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	13077000	USD
CY2020Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	20738000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13760000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18612000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	94364000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	91644000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	132839000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	143547000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	222278000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	245045000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	38463000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	38396000	USD
CY2021Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1292118000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1269375000	USD
CY2021Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6870000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	7185000	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7228000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7011000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	407678000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	441184000	USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	1437000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	1421000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-823914000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-777981000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	714000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5419000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	470355000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	498234000	USD
CY2021Q1	us-gaap	Minority Interest MinorityInterest	-938000	USD
CY2020Q4	us-gaap	Minority Interest MinorityInterest	-868000	USD
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	469417000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	497366000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	877095000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	938550000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26280000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13076000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	56434000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	41479000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16148000	USD
CY2021Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	625000	USD
CY2020Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	1548000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16119000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	72582000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	57598000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-46302000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-44522000	USD
CY2021Q1	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-45677000	USD
CY2020Q1	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-42974000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	262000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-45939000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-42974000	USD
CY2021Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-6000	USD
CY2020Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-61000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-45933000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-42913000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.32
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	143112000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	116060000	shares
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-45939000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-42974000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-4749000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1633000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	44000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	254000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-50644000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-44353000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-6000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-61000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-50638000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-44292000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	497366000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	15651000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-416000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7524000	USD
CY2021Q1	sgmo	Adjustments To Additional Paid In Capital Acquisition Of Noncontrolling Interest AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest	-64000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	4749000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	44000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-45939000	USD
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	469417000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	432739000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	409000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5620000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	1633000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	254000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-42974000	USD
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	394415000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-45939000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-42974000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1875000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1311000	USD
CY2021Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-824000	USD
CY2020Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	744000	USD
CY2021Q1	sgmo	Amortization And Other Changes In Right Of Use Assets AmortizationAndOtherChangesInRightOfUseAssets	-2023000	USD
CY2020Q1	sgmo	Amortization And Other Changes In Right Of Use Assets AmortizationAndOtherChangesInRightOfUseAssets	-1886000	USD
CY2021Q1	sgmo	Gain Loss On Free Shares GainLossOnFreeShares	-27000	USD
CY2020Q1	sgmo	Gain Loss On Free Shares GainLossOnFreeShares	-73000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7524000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5620000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-61000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	244000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1522000	USD
CY2020Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	43580000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-29939000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1741000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	100000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3829000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	345000	USD
CY2021Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-7561000	USD
CY2020Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-4965000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-20047000	USD
CY2020Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-8319000	USD
CY2021Q1	sgmo	Increase Decrease In Long Term Portion Of Lease Liabilities IncreaseDecreaseInLongTermPortionOfLeaseLiabilities	-1045000	USD
CY2020Q1	sgmo	Increase Decrease In Long Term Portion Of Lease Liabilities IncreaseDecreaseInLongTermPortionOfLeaseLiabilities	-887000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	800000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	169000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-68550000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18890000	USD
CY2021Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	97935000	USD
CY2021Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	144369000	USD
CY2020Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	71075000	USD
CY2021Q1	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	6870000	USD
CY2020Q1	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	0	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7950000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3775000	USD
CY2021Q1	us-gaap	Payments To Acquire Additional Interest In Subsidiaries PaymentsToAcquireAdditionalInterestInSubsidiaries	65000	USD
CY2020Q1	us-gaap	Payments To Acquire Additional Interest In Subsidiaries PaymentsToAcquireAdditionalInterestInSubsidiaries	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	45289000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	23720000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	15651000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2021Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2234000	USD
CY2020Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	411000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1818000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	820000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15235000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	409000	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-328000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8354000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5321000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	132829000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	81928000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	124475000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	87249000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2953000	USD
CY2020Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1080000	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1356000	USD
CY2020Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2021Q1	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in estimates during the three months ended March 31, 2021.</span></div>
CY2021Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2021Q1	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	1500000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	122975000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	131329000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	85749000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	80428000	USD
CY2020Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1600000	USD
CY2021Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1500000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1500000	USD
CY2020Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1500000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1500000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	124475000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	132829000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	87249000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	81928000	USD
CY2021Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Other Risks</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the Condensed Consolidated Balance Sheets. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established policies relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments and issuers of investments to the extent recorded on the Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an investigational new drug application (“IND”) filed with the U.S. Food and Drug Administration for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company’s suppliers were interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.</span></div>
CY2021Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	506447000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	124000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	31000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	506540000	USD
CY2021Q1	sgmo	Cash Equivalents And Available For Sale Securities Amortized Cost CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost	554082000	USD
CY2021Q1	sgmo	Cash Equivalents And Available For Sale Securities Gross Unrealized Gain Before Tax CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax	124000	USD
CY2021Q1	sgmo	Cash Equivalents And Available For Sale Securities Gross Unrealized Loss Before Tax CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax	31000	USD
CY2021Q1	sgmo	Cash Equivalents And Available For Sale Securities CashEquivalentsAndAvailableForSaleSecurities	554175000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	560575000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	86000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	37000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	560624000	USD
CY2020Q4	sgmo	Cash Equivalents And Available For Sale Securities Amortized Cost CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost	613740000	USD
CY2020Q4	sgmo	Cash Equivalents And Available For Sale Securities Gross Unrealized Gain Before Tax CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax	86000	USD
CY2020Q4	sgmo	Cash Equivalents And Available For Sale Securities Gross Unrealized Loss Before Tax CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax	37000	USD
CY2020Q4	sgmo	Cash Equivalents And Available For Sale Securities CashEquivalentsAndAvailableForSaleSecurities	613789000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	464109000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	510094000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	42431000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	50530000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	506540000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	560624000	USD
CY2021Q1	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2020	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17614376	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14849728	shares
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	300000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	2700000	USD
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	2600000	USD
CY2021Q1	us-gaap	Variable Lease Cost VariableLeaseCost	700000	USD
CY2020Q1	us-gaap	Variable Lease Cost VariableLeaseCost	500000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1700000	USD
CY2021Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.062
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	4663000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6991000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	7089000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	7237000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	7308000	USD
CY2021Q1	sgmo	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	20037000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	53325000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	10980000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	42345000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3882000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	38463000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	42345000	USD
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y6M
CY2020Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021Q1	us-gaap	Contractual Obligation ContractualObligation	17961000	USD
CY2021Q1	sgmo	License Obligations LicenseObligations	900000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7524000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5620000	USD
CY2021Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020Q4	us-gaap	Minority Interest MinorityInterest	-868000	USD
CY2021Q1	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	64000	USD
CY2021Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-6000	USD
CY2021Q1	us-gaap	Minority Interest MinorityInterest	-938000	USD

Files In Submission

Name	View Source	Status
0001628280-21-008878-index-headers.html	Edgar Link	pending
0001628280-21-008878-index.html	Edgar Link	pending
0001628280-21-008878.txt	Edgar Link	pending
0001628280-21-008878-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_01a.jpg	Edgar Link	pending
image_141.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
sgmo-20210331.htm	Edgar Link	pending
sgmo-20210331.xsd	Edgar Link	pending
sgmo-20210331xex102.htm	Edgar Link	pending
sgmo-20210331xex103.htm	Edgar Link	pending
sgmo-20210331xex103001.jpg	Edgar Link	pending
sgmo-20210331xex103002.jpg	Edgar Link	pending
sgmo-20210331xex103003.jpg	Edgar Link	pending
sgmo-20210331xex103004.jpg	Edgar Link	pending
sgmo-20210331xex103005.jpg	Edgar Link	pending
sgmo-20210331xex103006.jpg	Edgar Link	pending
sgmo-20210331xex103007.jpg	Edgar Link	pending
sgmo-20210331xex103008.jpg	Edgar Link	pending
sgmo-20210331xex103009.jpg	Edgar Link	pending
sgmo-20210331xex103010.jpg	Edgar Link	pending
sgmo-20210331xex103011.jpg	Edgar Link	pending
sgmo-20210331xex103012.jpg	Edgar Link	pending
sgmo-20210331xex103013.jpg	Edgar Link	pending
sgmo-20210331xex103014.jpg	Edgar Link	pending
sgmo-20210331xex104.htm	Edgar Link	pending
sgmo-20210331xex311.htm	Edgar Link	pending
sgmo-20210331xex312.htm	Edgar Link	pending
sgmo-20210331xex321.htm	Edgar Link	pending
sgmo-20210331_cal.xml	Edgar Link	unprocessable
sgmo-20210331_def.xml	Edgar Link	unprocessable
sgmo-20210331_htm.xml	Edgar Link	completed
sgmo-20210331_lab.xml	Edgar Link	unprocessable
sgmo-20210331_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SGMO
Sangamo Therapeutics Inc Stock $sgmo

2021 Q1 Form 10-Q Financial Statement

#000162828021008878 Filed on May 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SGMO Sangamo Therapeutics Inc Stock $sgmo

2021 Q1 Form 10-Q Financial Statement

#000162828021008878 Filed on May 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SGMO
Sangamo Therapeutics Inc Stock $sgmo